Multiplex Assay Kit for Synuclein Alpha (SNCa) ,etc. by FLIA (Flow Luminescence Immunoassay)
SNC-A; aSYN; PD1; PARK1; PARK4; NACP; Non-A Beta Component Of Alzheimer's Disease Amyloid Precursor Protein; Non-A4 component of amyloid precursor
(Note: Up to 8-plex in one testing reaction)
- UOM
- FOB US$ 427.00 US$ 443.00 US$ 468.00 US$ 501.00 US$ 534.00 US$ 583.00 US$ 657.00 US$ 821.00
- Quantity
Overview
Properties
- Product No.LMB222Mu
- Organism SpeciesMus musculus (Mouse) Same name, Different species.
- ApplicationsFLIA Kit for Antigen Detection.
Research use only - DownloadInstruction Manual
- CategorySignal transductionNeuro science
Sign into your account
Share a new citation as an author
Upload your experimental result
Review

Contact us
Please fill in the blank.
Recovery
Matrices listed below were spiked with certain level of recombinant Synuclein Alpha (SNCa) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Synuclein Alpha (SNCa) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.
Matrix | Recovery range (%) | Average(%) |
serum(n=5) | 80-91 | 88 |
EDTA plasma(n=5) | 81-91 | 86 |
heparin plasma(n=5) | 78-88 | 83 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Synuclein Alpha (SNCa) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Synuclein Alpha (SNCa) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Synuclein Alpha (SNCa) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
Sample | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 98-105% | 92-105% | 92-103% | 93-105% |
EDTA plasma(n=5) | 85-102% | 79-102% | 97-105% | 87-96% |
heparin plasma(n=5) | 80-101% | 82-92% | 89-97% | 85-105% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
Reagents | Quantity | Reagents | Quantity |
96-well plate | 1 | Plate sealer for 96 wells | 4 |
Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
Pre-Mixed Magnetic beads (22#:SNCa) | 1 | Analysis buffer | 1×20mL |
Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
Instruction manual | 1 |
Assay procedure summary
1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

Test principle
Analyte-specific antibodies are pre-coated onto color-coded microparticles. Microparticles, standards, and samples are pipetted into wells and the immobilized antibodies bind the analytes of interest. After washing away any unbound substances, a biotinylated antibody cocktail specific to the analytes of interest is added to each well. Following a wash to remove any unbound biotinylated antibody, Streptavidin-Phycoerythrin conjugate (Streptavidin-PE), which binds to the biotinylated detection antibodies, is added to each well. A final wash removes unbound Streptavidin-PE and the microparticles are resuspended in buffer and read using the Luminex or Bio-Plex analyzer.The MFI developed is proportional to the concentration of analytes of interest in the sample.
Giveaways
Increment services
Citations
- Cerebrospinal fluid–based kinetic biomarkers of axonal transport in monitoring neurodegenerationPubMed: PMC3428100
- Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmissionPubMed: PMC3107939
- Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locusPubMed: PMC3265381
- Mutations of PARK Genes and Alpha-Synuclein and Parkin Concentrations in Parkinson’s DiseaseIntechopen:Source
- Apolipoprotein Eε4: A Biomarker for Executive Dysfunction among Parkinson's Disease Patients with Mild Cognitive Impairmentpubmed:29326545
- The anti-aging protein klotho alleviates injury of nigrostriatal dopaminergic pathway in 6-hydroxydopamine rat model of Parkinson's disease: Involvement of PKA/CaMKII/CREB signaling.pubmed:29107062
- Development and biochemical characterization of a mouse model of Parkinson's disease bearing defective glucocerebrosidase activityPubmed: 30521842
- Potential therapeutic effects of antagonizing adenosine A2A receptor, curcumin and niacin in rotenone-induced Parkinson's disease mice modelPubmed: 31820278
- Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson's diseasePubmed: 32084576
- Anti-α-synuclein ASO delivered to monoamine neurons prevents α-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeysPubmed: 32810825